Abstract
Pulmonary arterial hypertension is a chronic, progressive disease of the pulmonary vasculature resulting in poor outcomes if left untreated. The management of group 1 pulmonary arterial hypertension has included the use of prostanoids, phosphodiesterase-5 inhibitors, and endothelin receptor antagonists targeting the prostacyclin, endothelin-1, and nitric oxide pathways. Three new medications have been approved by the US Food and Drug Administration over the past couple of years. Macitentan is the newest endothelin receptor antagonist, riociguat is a soluble guanylate cyclase stimulator, and treprostinil diolamine is the first oral prostanoid. This review will focus on the key trials leading to their approval, special considerations for each medication, and their potential place in therapy. The use of combination therapy as initial therapy in pulmonary arterial hypertension will also be discussed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 264-272 |
| Number of pages | 9 |
| Journal | Therapeutic Advances in Chronic Disease |
| Volume | 6 |
| Issue number | 5 |
| DOIs | |
| State | Published - Sep 27 2015 |
Fingerprint
Keywords
- macitentan
- oral treprostinil
- pulmonary arterial hypertension
- riociguat
ASJC Scopus subject areas
- Medicine (miscellaneous)
Cite this
Medical treatment update on pulmonary arterial hypertension. / Enderby, Cher Y.; Burger, Charles Dwayne.
In: Therapeutic Advances in Chronic Disease, Vol. 6, No. 5, 27.09.2015, p. 264-272.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Medical treatment update on pulmonary arterial hypertension
AU - Enderby, Cher Y.
AU - Burger, Charles Dwayne
PY - 2015/9/27
Y1 - 2015/9/27
N2 - Pulmonary arterial hypertension is a chronic, progressive disease of the pulmonary vasculature resulting in poor outcomes if left untreated. The management of group 1 pulmonary arterial hypertension has included the use of prostanoids, phosphodiesterase-5 inhibitors, and endothelin receptor antagonists targeting the prostacyclin, endothelin-1, and nitric oxide pathways. Three new medications have been approved by the US Food and Drug Administration over the past couple of years. Macitentan is the newest endothelin receptor antagonist, riociguat is a soluble guanylate cyclase stimulator, and treprostinil diolamine is the first oral prostanoid. This review will focus on the key trials leading to their approval, special considerations for each medication, and their potential place in therapy. The use of combination therapy as initial therapy in pulmonary arterial hypertension will also be discussed.
AB - Pulmonary arterial hypertension is a chronic, progressive disease of the pulmonary vasculature resulting in poor outcomes if left untreated. The management of group 1 pulmonary arterial hypertension has included the use of prostanoids, phosphodiesterase-5 inhibitors, and endothelin receptor antagonists targeting the prostacyclin, endothelin-1, and nitric oxide pathways. Three new medications have been approved by the US Food and Drug Administration over the past couple of years. Macitentan is the newest endothelin receptor antagonist, riociguat is a soluble guanylate cyclase stimulator, and treprostinil diolamine is the first oral prostanoid. This review will focus on the key trials leading to their approval, special considerations for each medication, and their potential place in therapy. The use of combination therapy as initial therapy in pulmonary arterial hypertension will also be discussed.
KW - macitentan
KW - oral treprostinil
KW - pulmonary arterial hypertension
KW - riociguat
UR - http://www.scopus.com/inward/record.url?scp=84940020648&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84940020648&partnerID=8YFLogxK
U2 - 10.1177/2040622315590757
DO - 10.1177/2040622315590757
M3 - Article
AN - SCOPUS:84940020648
VL - 6
SP - 264
EP - 272
JO - Therapeutic Advances in Chronic Disease
JF - Therapeutic Advances in Chronic Disease
SN - 2040-6223
IS - 5
ER -